GSK Will Buy Arixtra From Sanofi If Aventis Merger Goes Through
Executive Summary
GlaxoSmithKline's conditional acquisition of Sanofi's antithrombotic brands would give GSK an almost free chance to build a potentially significant new product line in the U.S
You may also be interested in...
Sanofi-Aventis Begins Operations; Markham, Senior Aventis Execs Depart
Sanofi-Aventis is beginning operations as a top 10 pharmaceutical company in the U.S
Sanofi-Aventis Begins Operations; Markham, Senior Aventis Execs Depart
Sanofi-Aventis is beginning operations as a top 10 pharmaceutical company in the U.S
Arixtra adds treatment indications
Sanofi-Synthelabo's antithrombotic Arixtra (fondaparinux) clears FDA May 28 for treatment of deep vein thrombosis and pulmonary embolism. The product, previously approved for prophylactic use in patients undergoing hip fracture surgery and hip or knee replacement, is being divested to GlaxoSmithKline in conjunction with Sanofi's pending acquisition of Aventis (1"The Pink Sheet" April 19, 2004, p. 18)...